PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2010-02-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 635
- Registration Number
- NCT00136916
- Locations
- π΅π·
Pfizer Investigational Site, San Juan, Puerto Rico
Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 755
- Registration Number
- NCT00134238
- Locations
- π³π±
Pfizer Investigational Site, Utrecht, Netherlands
A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2009-08-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 282
- Registration Number
- NCT00134199
- Locations
- πΊπΈ
Pfizer Investigational Site, Tacoma, Washington, United States
A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15067
- Registration Number
- NCT00134264
- Locations
- π¬π§
Pfizer Investigational Site, Warwick, United Kingdom
A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2008-04-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1100
- Registration Number
- NCT00134147
- Locations
- π¬π§
Pfizer Investigational Site, York, United Kingdom
A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2007-12-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1100
- Registration Number
- NCT00134173
- Locations
- πͺπΈ
Pfizer Investigational Site, Madrid, Spain
A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2007-11-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 160
- Registration Number
- NCT00134498
- Locations
- π¨π¦
Pfizer Investigational Site, Ste-Foy, Quebec, Canada
Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2007-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00134511
- Locations
- πΏπ¦
Pfizer Investigational Site, Cape Town, South Africa
Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2007-10-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 400
- Registration Number
- NCT00134485
- Locations
Pfizer Investigational Site
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
- Conditions
- First Posted Date
- 2005-08-16
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00130897
- Locations
- π»πͺ
Pfizer Investigational Site, Caracas, Estado Miranda, Venezuela
Β© Copyright 2024. All Rights Reserved by MedPath